Pediatric Allogeneic Hematopoietic Stem Cell Transplantation in Korea: April 2000: The Korean Society of Pediatric Hematology-Oncology.
- Author:
Bin CHO
1
Author Information
1. Department of Pediatrics, The Catholic University of Korea, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Stem cell transplantation;
Bone marrow transplantation
- MeSH:
Anemia, Aplastic;
Bone Marrow Transplantation;
Child;
Disease-Free Survival;
Female;
Fetal Blood;
Follow-Up Studies;
Hematopoietic Stem Cell Transplantation*;
Hematopoietic Stem Cells*;
Humans;
Korea;
Leukemia, Myeloid, Acute;
Male;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
Rare Diseases;
Siblings;
Stem Cell Transplantation;
Stem Cells
- From:Korean Journal of Pediatric Hematology-Oncology
2001;8(1):1-8
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The Korean Society of Pediatric Hematology-Oncology surveyed pediatric allogeneic hematopoietic stem cell transplantation in Korea. From 1983 to April 2000, 267 children underwent allogeneic hematopoietic stem cell transplantation. Seventy-nine children were transplanted for acute myelogenous leukemia (AML), 76 for severe aplastic anemia (SAA), 62 for acute lymphoblastic leukemia (ALL), 44 for chronic myelogenous leukemia/myelodysplastic syndrome (CML/MDS) and 11 for nonmalignant rare disease. There were 152 males and 115 females with a median age of 9 years and median follow-up of 25 months. One hundred and eighty-nine of 267 cases were HLA-matched sibling transplants. The estimated event-free survival (EFS) of patients with SAA who underwent HLA-matched sibling transplants is 89%. The estimated EFS of ALL in CR1 and CR2 are 77% and 67%, respectively. The estimated EFS of AML in CR1 and CR2 are 73% and 60%, respectively. The estimated EFS of AML in CR1 prepared with Bu/Cy is 82%. The estimated EFS of CML/MDS is 71%. Eight out of 10 children with nonmalignant rare disease who underwent HLA-matched transplants are alive with disease free. Thirty-three children underwent unrelated bone marrow transplantation and 17 cord blood transplantation. Outcomes of patients with alternative stem cell sources are not estimated due to short median follow-up. These data shows that allogeneic hematopoietic stem cell transplantation is a curative method for children with hematopoietic stem cell disorders and we wish to share these results.
